Olezarsen
Based on 1 Customer Validation
Olezarsen (ISIS 678354;IONIS-APOCIII-LRx) is a GalNAc-modified antisense oligonucleotide. Olezarsen binds to APOC3 mRNA and induces its degradation via ribonuclease H1-mediated sense strand cleavage, thereby reducing hepatic apolipoprotein C-III (apoC-III) synthesis. Olezarsen reduces plasma triglyceride, apolipoprotein B and non-high-density lipoprotein cholesterol levels. Olezarsen is applicable to research related to familial chylomicronemia syndrome, hypertriglyceridemia and atherosclerotic cardiovascular disease.
For research use only. We do not sell to patients.
- Purity: 96.60%
- CAS No.: 2097587-83-0
- Molecular Weight:8684.86
-
Storage:
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Biological Activity
|
apoC3 |
Chemical Information
-
CAS No. 2097587-83-0
-
Appearance Solid
-
Molecular Weight 8684.86
-
Color White to off-white
-
SMILES
[Olezarsen]
-
Synonyms
ISIS 678354; IONIS-APOCIII-LRx; AKCEA-APOCIII-LRx
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Purity & Documentation
-
Data Sheet (267 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2242 KB)
References
[1]. Stroes ESG, et al. Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome. N Engl J Med. 2024;390(19):1781-1792. [Content Brief]
[2]. Karwatowska-Prokopczuk E, Tardif JC, Gaudet D, et al. Effect of olezarsen targeting APOC-III on lipoprotein size and particle number measured by NMR in patients with hypertriglyceridemia. J Clin Lipidol. 2022;16(5):617-625. [Content Brief]
[3]. Bergmark BA, et al. Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk. N Engl J Med. 2024;390(19):1770-1780. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)